Relmada Therapeutics (RLMD) Tops Q2 EPS by 10c
Tweet
Share
E-mail
Get Alerts RLMD Hot Sheet
Join SI Premium – FREE
Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.30), $0.10 better than the analyst estimate of ($0.40).
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic, Samsung in talks for custom AI chip - The Information
- Infineon opens €5B chip fab in Dresden ahead of schedule
- Susquehanna Downgrades Greenbrier Companies (GBX) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
